Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hyperinsulinism|HER2-negative Breast Cancer
Interventions: DRUG: Dapagliflozin 10mg
Sponsor: Yale University
Collaborators: AstraZeneca